Excelsior Correspondent
JAMMU, Mar 31: Haemophilia & Health Collective of North India (HHCN) organized academic colloquium /CME on “Changing landscape of the Haemophilia care: Unmet needs & solutions” in Dehradun the other day.
It was a focussed-group academic programme to disscus & deliberate upon enhancing the clinical care & patient adherence for Haemophilia under the changing scenario with the availability of drug products (SHL, EHL & NFT). Experts on the subject who were invited from North India among others included Dr Naresh Gupta, chairperson HHCN , Medical advisor Haemophilia LNJP Hospital & former Director Prof. MAMC New Delhi; Dr KK Kaul, President HHCN, Medical advisor J&K Thalassaemia Welfare Society, former Prof.& Head PG Dept. of Pathology & Chief Nodal officer CHCC GMC Jammu; Dr Sunita Agarwal Prof & I/C Haemoplilia care center MAMC & LNJP Hospital New Delhi; Dr Tulika Seth, Prof. Haematology AIIMS New Delhi; Prof. S.Bilal, HoD Pathology & I/C Haemophilia Center GMC Srinagar; Dr Girsh Kumar, Assoc. Prof. Paediatrics Hamirpur (HP). Dr RK Nigam, Prof. Pathology Gandhi Medical Collage Bhopal; Dr Rubi Khan Deputy Director NHM Bhopal, Dr Sudhir Atri, Senior Prof. Haematology PGIMS, Rohtak; Prof. Sanjeev Dingra, an eminent Paediatrician GMC Jammu; Dr Ankur Jain, Haematologist Safderjang Hospital, New Delhi.
Dr Naresh Gupta highlighted the meeting objectives and spoke briefly about the emerging therapies for better Haemophilia care. Dr Tulika Seth discussed in detail about the advances in Haemophilia A & B management. Dr Sunita Aggarwal spoke on unmet needs in Haemophilia among the present standard of care. Improving adherence and confidence among persons with Haemophilia (PWH) was discussed by Dr Bilal.
This was followed by workshop in which newly developed drug products which are undergoing final trials were deliberated upon. The main focus remained especially on anti -Tissue factor pathway inhibitor (anti-TFPI) which is effective in both types of Haemophilia (A&B) with or without inhibitors.
Dr Kaul sought detailed clarification about the level of Thrombin generation in the patient using these novel therapies so that safe and optimal dose schedule especially of anti TFPI is scientifically defined based on laboratory monitoring as well as clinical outcome. Dr Kaul said that adoption of these pen devices in Haemophilia care is a crucial unmet need and shall be a game changer towards a better future for PWH. He said the cure of Haemophilia is possible in near future by gene therapy and its trial on one patient has began at CMC Vellore.
Trending Now
E-Paper
Follow our WhatsApp channel